You are here: Industry Insights > Tiziana

News List

Tiziana and FHI Clinical work on Phase II intranasal Covid-19 drug trial pharmaceutical-technology
June 25, 2021
Tiziana Life Sciences has entered an agreement with FHI Clinical to carry out a Phase II proof-of-concept clinical trial of intranasal Foralumab in severe Covid-19 patients hospitalised with pulmonary inflammation in Brazil.
Tiziana to commence trial of nasal Covid-19 monoclonal antibody pharmaceutical-technology
March 31, 2021
Tiziana Life Sciences is set to commence a Phase II trial of its nasal anti-CD3 human monoclonal antibody (mAb), Foralumab, in moderate to severe hospitalised Covid-19 patients in Brazil.
Tiziana’s Foralumab suppresses lung inflammation in Brazil Covid-19 trial pharmaceutical-technology
February 04, 2021
Tiziana Life Sciences has reported positive data from an exploratory clinical study in Brazil evaluating its nasally administered anti-CD3 human monoclonal antibody, Foralumab, in Covid-19 patients.
USPTO grants patent to Tiziana for fully human monoclonal antibody, TZLS-501 expresspharma
August 25, 2020
The grant of this additional patent on TZLS-501 is of significance for the potential treatment of COVID-19 and other pulmonary diseases.
Tiziana Developing TZLS-501 as Potential Coronavirus Treatment americanpharmaceuticalreview
March 13, 2020
Tiziana Life Sciences has announced that its TZLS-501 treatment could be a potential treatment for patients infected with coronavirus (COVID-19) who are at risk of respiratory failure.